Summary Membrane-associated phospholipase A2 (M-PLA2) is an enzyme that hydrolyses the sn-2 fatty acyl ester bond of phosphoglycerides. We measured M-PLA2 concentration in tissue extracts from 325 human breast cancers using a specific radioimmunoassay recently developed. Correlation analyses between the tissue concentration of M-PLA2 and clinicopathological factors showed that the enzyme level was significantly higher in patients with distant metastasis than in those without. In addition, M-PLA2 concentration was significantly higher in scirrhous carcinoma than in other histological types. No significant association was found between M-PLA2 concentration and age, menstrual status, tumour size, histological grade, vessel involvement or oestrogen receptor (ER) and progesterone receptor (PR) status. The expression of M-PLA2 mRNA was examined in a fibroadenoma, a stage IV breast cancer and its metastatic site of skin. Northern blot analysis showed a clear hybridisation band corresponding to M-PLA2 mRNA in both primary breast cancer and its metastatic site, while the fibroadenoma expressed a faint band corresponding to M-PLA2 mRNA. Breast cancer patients with high M-PLA2 concentrations exhibited significantly shorter disease-free and overall survival than those with low M-PLA2 concentration at the cut-off point of 5 ng 100 mg-' protein, which was determined in a separate study. In multivariate analysis, M-PLA2 was found to be an independent prognostic factor for disease recurrence and death in human breast cancer. The possible significance of M-PLA2 expression in human breast cancer tissue is discussed.
Phospholipase A2 is a lipolytic enzyme that specifically hydrolyses the 2-acyl position of a glycerophospholipid (Vadas & Pruzanski, 1986 ). There are two structurally different forms of phospholipase A2 (PLA2): groups I and II (Heinrikson et al., 1977; Kanda et al., 1989) . Group I PLA2 is often characterised as the pancreatic type as it is abundant in pancreatic secretions. Group II PLA2 was initially divided into two types -membrane-associated PLA2 (M-PLA2) and secretory PLA2 -but later studies demonstrated that these two types are identical (Kanda et al., 1989; Seilhamer et al., 1989) . Group I PLA2 has been investigated by many researchers in relation to several diseases, such as acute pancreatitis, but little is known about the physiological role of group II PLA2, despite the presence of this form in a variety of mammalian cells (van den Bosch, 1980) .
Recently, we developed a specific radioimmunoassay for human M-PLA2 (Matsuda et al., 1991) and reported that the tissue concentration of M-PLA2 in human breast cancer is likely to be a prognostic factor (S. Yamashita et al., 1993) . In the previous study including 78 patients (S. Yamashita et al., 1993) , we determined the optimal cut-off point of 50 ng 100 mg-' protein according to the method of Tandon et al. (1990) . However, creating a cut-off point for continuous variables and then using it on the same data set inevitably leads to optimistic results. Therefore, we have now extended this study and determined M-PLA2 concentrations in tissue extracts from another group of 325 patients with breast cancer, and evaluated the prognostic significance of this enzyme in human breast cancer using the cut-off point determined previously (S. Yamashita et al., 1993) . In addition, we have investigated the expression of M-PLA2 mRNA in both the primary site and metastatic site of human breast cancer. This study provides evidence for a possible significance of M-PLA2 expression in the progression of human breast cancer.
Materials and methods

Patients
The 325 breast cancer patients analysed in this study are those who underwent curative or non-curative mastectomy in Society (1988) , and was graded in parallel according to the criteria described by Bloom and Richardson (1957) , except for 12 comedocarcinomas. ER and PR were determined by the dextran-coated charcoal method as described previously (McGuire et al., 1977) . The results of ER and PR were summarised as negative (<10fmolmg-1 protein) or positive (>l10fmolmg-1 protein).
Assay for M-PLA2 Tumour samples were drawn from a pool of frozen specimens (stored at -80C) and each specimen was homogenised and extracted with 50 mM Tris-HCl buffer (pH 7.4) containing 0.25% Triton X-100 (Sigma, St Louis, MO, USA) as described previously (Yamashita et al., 1986) . M-PLA2 concentration was measured by a radioimmunoassay using anti-M-PLA2 monoclonal antibody as described by Matsuda et al. (1991) . There is no cross-reactivity of this antibody with human P-PLA2, pancreatic trypsin, chymotrypsin, elastase 1 and pancreatic secretory trypsin inhibitor (Matsuda et al., 1991) . The purified M-PLA2 was iodinated with [125I]sodium iodide (New England Nuclear, Boston, MA, USA) by the chloramine-T method (Hunter & Greenwood, 1962) , and the 251I-labelled M-PLA2 was purified by gel filtration on a PD-10 column (Pharmacia Fine Chemicals, Sweden). Its specific activity was approximately 3.5 MBq ftg '. The detection limit of M-PLA2 is 7 ng 100 mg-' protein. The intra-assay coefficient of variation (CV) was obtained by testing one sample on the same kit ten times. Those for the high, middle and low sample levels were 3.8, 5.6 and 5.7% respectively. The interassay CV was calculated from assays using the same sample during a period of 1 month, and those for the three sample levels were 4.4, 4.5 and 3.2% respectively.
Northern blot analysis Total RNA was extracted from a fibroadenoma, a primary breast cancer and its metastasis to skin by the guanidine thiocyanate-caesium chloride procedure (Sambrook et al., 1989) . Total RNA (51tg per lane) was separated by 1% agarose-formaldehyde gels, and transferred to nylon membrane (Hybond N+) by Northern blotting. The blots were hybridised with 32P-labelled specific probes. The 336 bp NcoI-ScaI fragment of group II PLA2 cDNA (Seilhamer et al., 1989) was used for its mRNA detection. Filters were washed in 0.2 x SSC and 0.1% SDS at 65°C. As a control, filters were stripped and rehybridised with a radiolabelled G3PDH probe. The bands were quantitated by a BAS2000 image analyser.
Statistics
The Kruskal-Wallis test was used for the analysis of M-PLA2 concentration in relation to clinicopathological factors. The Cox proportional hazards model (Cox, 1972) was used in multivariate analysis to assess the independent prognostic significance. 
Results
Relation between M-PLA2 concentration and clinicopathological factors M-PLA2 was detected in tissue extracts from 311 of 325 specimens, the concentration ranging from 7.3 to 1,755 ng 100 mg-' protein. The median value of M-PLA2 concentration was 52 ng 100 mg-' protein. Table I shows the correlation between M-PLA2 concentration and the characteristics of the patients. When M-PLA2 concentration was compared in terms of age, menstrual status, tumour size, nodal status, histological grade, vessel involvement, ER and PR, no significant association was found between M-PLA2 concentration and any of these features. However, M-PLA2 concentration was significantly higher in scirrhous carcinoma than in other histological types (P = 0.0 16). Similarly, M-PLA2 concentration was significantly higher in distant metastatsispositive than in -negative patients (P = 0.025).
Relation between M-PLA2 concentration and survival To evaluate the prognostic significance of M-PLA2, we analysed disease-free survival and overall survival in 290 breast cancer patients. Thirty-five patients with distant metastases at the time of primary therapy were excluded from this analysis. The cut-off point of 50 ng 100 mg-' protein was used because our previous study of another group of patients demonstrated that this cut-off point could give a statistically significant separation for risk of relapse according to the method of Tandon et al. (1990) . This cut-off point is close to the median value (52 ng 100 mg-protein) of the present series. As shown in Figure 1 Number of paitents in each group: high M-PLA2, 133; low M-PLA2, 157.
cancer tissue containing a high concentration of M-PLA2 had a significantly shorter disease-free survival (P = 0.008) and overall survival (P = 0.011) time than those with a low content of the enzyme. In multivariate analysis including all variables, M-PLA2 was found to be an independent prognostic factor for recurrence and for death of about the same import as lymph node involvement (Tables II and III) . (Matsuda et al., 1991) and in various clinical conditions such as endotoxic shock (Vadas & Hay, 1983) and multiple injuries (Uhl et al., 1990) , suggesting that this enzyme is one of the acute-phase reactants. We also showed that serum M-PLA2 concentration was significantly elevated in patients with various malignant tumours (Matsuda et al., 1991) . Since the incidence and magnitude of the elevation were greater in patients with advanced breast cancers than in those with early stages, we speculated that this enzyme might be produced by breast cancer cells themselves.
Immunohistochemical study showed that M-PLA2 was preferentially stained in breast cancer cells rather than breast stromal cells (Yamashita et al., 1993) , indicating that breast cancer cells produce a large amount of this enzyme.
In the present study, correlation analyses showed that tissue M-PLA2 level was significantly higher in distant metastasis-positive than in -negative patients. Furthermore, of interest was the finding that the distant metastasis from a stage IV carcinoma showed even larger amounts of M-PLA2 mRNA than the primary tumour. These results suggest that the expression of this enzyme may be related to the metastatic potency of human breast cancer.
Histologically scirrhous carcinoma, which is characterised by its prominent stromal cellularity, was also related to high M-PLA2 concentrations in tissue extracts. In our previous report, the intensity of immunohistochemical staining was (~~~~~~~~~-4 QO _ 28S _ 18S
G3PDH
Figure 2 Northern blot analysis of total RNA from a fibroadenoma, a primary breast cancer and its metastasis to skin. Total RNA was hybridised with cDNA from human group II PLA2 as probe. To assess equal load of mRNA per lane, the filter was subsequently hybridised to a G3PDH probe. 28S and 18S rRNA bands were used as molecular weight markers. Yamashita et al., 1993) . Recently, we found that human M-PLA2 itself has a mitogenic effect on fibroblasts (Kurizaki et al., 1992) . In addition, M-PLA2 augments the production of prostaglandin E2 (PGE2), which is known to stimulate mitogenesis in fibroblasts (Nolan et al., 1988; Hara et al., 1991) . These findings suggest that M-PLA2 may play an important role in stimulating the growth of stromal cells in breast cancer tissues in a paracrine fashion. Further, PGE2 released at the tumour site inhibits the host immunological response and enhances tumour growth (Balch et al., 1984; Okada et al., 1990) . The release of fatty acids is at least two orders of magnitude greater than eicosanoid production, and these fatty acids also have many direct biological effects on normal and malignant cells (Imagawa et al., 1989; Clerc et al., 1991) .
M-PLA2
Reliable predictors of survival or relapse in patients with breast cancer aid in determining the use of adjuvant chemotherapy or endocrine therapy. Established prognostic indicators, such as age, lymph node involvement, tumour grade and hormone receptor status, assist in predicting patient outcome or response to treatment, but are not entirely dependable. Several enzymes determined in the cytoplasm and organelles of tumour cells have been found to have prognostic value in human breast cancer. Most of these enzymes are proteinases, such as plasminogen activator (Janicke et al., 1989; Duffy et al., 1990; J. Yamashita et al., 1993) and cathepsin D (Spyratos et al., 1989; Tandon et al., 1990) , which have been implicated in tumour infiltration and metastasis. The present study offers statistical evidence that M-PLA2 concentration in tissue extracts is an independent prognostic factor that clearly identifies high-and low-risk patients using a cut-off point determined previously. To our knowledge, this is the first lipolytic enzyme which can be added to the list of second-generation prognostic factors in human breast cancer.
In conclusion, the present study provides evidence that M-PLA2 expression is closely associated with the malignant potential of human breast cancer and that this new biological factor can be an independent prognostic factor.
